FDA Approves First Generic Versions of FARXIGA - Summary - MDSpire
FDA & Government News

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Share

The FDA has approved the first generic versions of dapagliflozin (FARXIGA) for adults with type 2 diabetes facing cardiovascular risk. This sodium-glucose cotransporter 2 inhibitor helps reduce glucose and sodium reabsorption in the kidneys, improving glycemic control alongside lifestyle changes. With over 40 million Americans affected by diabetes, the generic tablets maintain consistent prescribing information with existing branded options. Safety concerns include risks of diabetic ketoacidosis and common infections, encouraging healthcare providers to refer to the Orange Book for product details.

Original Source(s)

FDA Approves First Generic Versions of FARXIGA

  • by Kathryn Wighton

  • April 7, 2026

Related Content

The Missing Piece in the Dark Metabolome Puzzle?

Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions

Wegovy and Possible Vision Risk

Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists

  • April 8, 2026

  • 3 min
Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access